Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is anticipated to see continued growth in the coming years, driven by its strong and differentiated product portfolio, which includes Crysvita, Mepsevii, and Dojolvi. The company's upcoming regulatory and development milestones, such as the potential FDA approval of GTX-102 for rare diseases, could unlock additional upside potential. While the company may face challenges in gaining product labels, its track record of employing accelerated strategies and its robust pipeline position it for long-term success. Based on the latest financials, we maintain our Buy rating but have lowered our 12-month price target to $50 per share to reflect our reduced revenue growth expectations.

Ultragenyx Pharmaceutical is facing headwinds in terms of its expected revenue growth, with forecasted revenue for FY26 falling below analyst expectations and not reaching profitability until FY27. Furthermore, its planned expense reduction includes one-time restructuring charges and relies on the receipt and monetization of two PRVs. Additionally, while there are upcoming value inflection points such as the potential FDA approval of DTX401 in 2H26, multiple assets in the development stage are not factored into our valuation assessment, leaving room for future success to drive meaningful upside. Ultragenyx may be able to achieve full-year GAAP profitability in 2027, but these uncertainties and potential delays make it a risky investment with a negative outlook.